National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Apalutamide (Erleada®) is indicated for the treatment of non-metastatic castration resistant prostate cancer (nmCRPC) at high risk of developing metastatic disease.


NCPE Assessment Process Complete
Rapid review commissioned 30/01/2019
Rapid review completed 27/02/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of apalutamide in combination with ADT compared with the current standard of care.